17
ASHI Quarterly Third Quarter 2015
C U R R E N T L I T E R A T U R E R E V I E W
Conclusions
Based on current literature, it appears that pre-existing antibodies
in mismatched (haploidentical, mismatched unrelated,
mismatched cord blood) SCT patients can delay and/or
decrease the engraftment process and even result in complete
graft failure Conversely, transfer of sensitized B cells from the
BMT/HSCT donors that have HLA-specific antibodies against
mismatched HLA antigens of the recipients (DRSA) can cause
B cell-mediated GVHD Hence, HLA antibody monitoring of
BMT/HSCT patients and donors may be helpful in choosing the
optimal donor/recipient pair When there is no choice except a
mismatched BMT/HSCT and the recipient or donor has reactive
anti-HLA antibodies, desensitization or treatment with rituximab
may bring about a favorable outcome
References
1 Spellman S, Bray R, Rosen-Bronson S, et al The detection of
donor-directed, HLA-specific alloantibodies in recipients of
unrelated hematopoietic cell transplantation is predictive of graft
failure Blood. 2010;115:2704–2708
2 Ciurea SO, Thall PF, Wang X, et al Donor-specific anti-HLAAbs
and graft failure in matched unrelated donor hematopoietic stem
cell transplantation Blood. 2011;118:5957–5964
3 Takanashi M, Atsuta Y, Fujiwara K, et al The impact of anti-
HLA antibodies on unrelated cord blood transplantations Blood.
2010;116:2839–2846
4 Cutler C, Kim HT, Sun L, et al Donor-specific anti-HLA antibodies
predict outcome in double umbilical cord blood transplantation
Blood. 2011;118:6691–6697
5 Ciurea SO, de Lima M, Cano P, et al High risk of graft failure in
patients with anti-HLA antibodies undergoing haploidentical stem-
cell transplantation Transplantation. 2009;88:1019–1024
6 Yoshihara S, Maruya E, Taniguchi K, et al Risk and prevention
of graft failure in patients with preexisting donor-specific HLA
antibodies undergoing unmanipulated haploidentical SCT Bone
Marrow Transplant. 2012;47:508–515
7 Gladstone DE, Zachary AA, Fuchs EJ, et al Partially mismatched
transplantation and human leukocyte antigen donor-specific
antibodies Biol Blood Marrow Transplant. 2013;19:647-52
8 Taniguchi K, Yoshihara S, Maruya E, et al Donor-derived HLA
antibody production in patients undergoing SCT from HLA
antibody-positive donors Bone Marrow Transplant. 2012;47:1338-42
9 Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, et al The role
of B cells in the pathogenesis of graft-versus-host disease Blood.
2009;114:4919-27
10 Hows J, Beddow K, Gordon-Smith E, et al Donor-derived red
blood cell antibodies and immune hemolysis after allogeneic bone
marrow transplantation Blood. 1986;67:177–181
11 Toren A, Dacosta Y, Manny N, Varadi G, Or R, Nagler A Passenger
B-lymphocyte induced severe hemolytic disease after allogeneic
peripheral blood stem cell transplantation Blood. 1996;87:843–844
12 Lee HJ, Gulbis A, De Padua Silva L, et al Rituximab for passenger
lymphocyte syndrome associated with allogeneic SCT Bone Marrow
Transplant. 2008;42:67–69; Adams BR, Miller AN, Costa LJ Self-
limited hemolysis due to anti-D passenger lymphocyte syndrome
in allogeneic hematopoietic stem cell transplantation Bone Marrow
Transplant. 2010;45:772–773
13 Kamble R, Oholendt M, Carrum G Rituximab responsive
refractory acute graft-versus-host disease Biol Blood Marrow
Transplant. 2006;12(11):1201-1202
14 Ratanatharathorn V, Logan B, Wang D, et al Prior rituximab
correlates with less acute graft-versus-host disease and better survival
in B-cell lymphoma patients who received allogeneic peripheral
blood stem cell transplantation Br J Haematol. 2009;145(6):816-824
15 KhouriI F, McLaughlinP, Saliba RM, et al Eight-year experience
with allogeneic stem cell transplantation for relapsed follicular
lymphoma after nonmyeloablative conditioning with fludarabine,
cyclophosphamide, and rituximab Blood. 2008;111(12):5530-5536
16 Kebriaei P, Saliba RM, MaC, et al Allogeneic hematopoietic stem
cell transplantation after rituximab-containing myeloablative
preparative regimen for acute lymphoblastic leukemia Bone Marrow
Transplant. 2006;38(3):203-209
17 Shimoni A, Hardan I, Avigdor A, et al Rituximab reduces relapse
risk after allogeneic and autologous stem cell transplantation in
patients with high-risk aggressive non-Hodgkin's lymphoma Br J
Haematol. 2003;122(3):457-464
18 Kharfan-Dabaja MA, Tate C, Perkins J, et al Administration of
rituximab is feasible and does not affect engraftment of allograft
recipients with advanced CD20+ malignancies [abstract 3016]
Blood. 2007;110(11)
19 Sahaf B, Chen G, Heydari K, Arai S, Miklos D Rituximab infusion
two months after hct decreases alloreactive b cell responses while
recipient plasma cells persist [abstract 2234] Blood. 2008;112(11)
20 Iori AP, Torelli GF, De Propris MS, et al B-cell concentration in
the apheretic product predicts acute graft-versus-host disease and
treatment-related mortality of allogeneic peripheral blood stem cell
transplantation Transplantation. 2008;85(3):386-390
Corresponding Author Information
Siva Kanangat, PhD, D (ABHI)
Director & Associate Professor
Histocompatibility & Immunogenetics
Department of Pathology
Rush University Medical Center • Chicago, IL 60612
Phone: 312-942-2054 • Email: Sivadasan_kanangat@rush edu
Recommended Reading:
Yoshihara S, Taniguchi K, Ogawa H, Saji H The role of
HLA antibodies in allogeneic SCT: is the 'type-and-screen'
strategy necessary not only for blood type but also for HLA?
Bone Marrow Transplant. 2012; doi: 10 1038/bmt 2011 249